From discovery to clinical validation, our pipeline is designed to deliver impact where it’s needed most.
Advancing a pipeline of therapies designed to address rare, underserved, and resistant conditions. Anchored in mechanistic science, durable IP, and smart clinical execution.
Advancing a pipeline of therapies designed to address rare, underserved, and resistant conditions. Anchored in mechanistic science, durable IP, and smart clinical execution.
Featured Programs
Featured Programs
Malignant Fungating Wounds (MFW)
Uveitis
Program: VT1953 Gel
Status: Clinical Development
Malignant fungating wounds estimated affect up to 5%-14% of advanced cancer patients worldwide, causing severe pain, malodor, and social isolation. There are currently no approved drugs—patients rely on suboptimal off-label treatments.
VT1953 is a first-in-class gel designed to:
Target DNA-gyrase to reduce the bacterial drivers of malodor.
Inhibit the TLR-MD2 inflammation pathway to decrease pain and inflammation.
With its dual mechanism and strong clinical rationale, VT1953 has the potential to dramatically improve the quality of life for cancer patients suffering from MFW, while pursuing an attractive orphan regulatory pathway.
Malignant Fungating Wounds (MFW)
Uveitis
Program: VT1953 Gel
Status: Clinical Development
Malignant fungating wounds estimated affect up to 5%-14% of advanced cancer patients worldwide, causing severe pain, malodor, and social isolation. There are currently no approved drugs—patients rely on suboptimal off-label treatments.
VT1953 is a first-in-class gel designed to:
Target DNA-gyrase to reduce the bacterial drivers of malodor.
Inhibit the TLR-MD2 inflammation pathway to decrease pain and inflammation.
With its dual mechanism and strong clinical rationale, VT1953 has the potential to dramatically improve the quality of life for cancer patients suffering from MFW, while pursuing an attractive orphan regulatory pathway.
Malignant Fungating Wounds (MFW)
Uveitis
Program: VT1953 Gel
Status: Clinical Development
Malignant fungating wounds estimated affect up to 5%-14% of advanced cancer patients worldwide, causing severe pain, malodor, and social isolation. There are currently no approved drugs—patients rely on suboptimal off-label treatments.
VT1953 is a first-in-class gel designed to:
Target DNA-gyrase to reduce the bacterial drivers of malodor.
Inhibit the TLR-MD2 inflammation pathway to decrease pain and inflammation.
With its dual mechanism and strong clinical rationale, VT1953 has the potential to dramatically improve the quality of life for cancer patients suffering from MFW, while pursuing an attractive orphan regulatory pathway.
A Cambridge, MA, based global healthcare platform synergizing biotech, medical devices, and AI.
Vyome Holdings, Inc.
Nasdaq: HIND
PRINCIPAL OFFICE
Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138
PHONE
+1 973-832-8147
SUBSIDIARIES
Vyome Therapeutics, Inc.
OFFICE
Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138
Vyome Therapeutics Limited, Subsidiary of Vyome Therapeutics, Inc.
OFFICE
Plot No. 465, Ground Floor, F.I.E., Patparganj Industrial Area, Delhi, India- 110092.
PHONE
+91-99682-17333
*Certain statements on this site are forward-looking within the meaning of federal securities laws. Please see our full disclaimer here.
Vyome Holdings, Inc.
Nasdaq: HIND
PRINCIPAL OFFICE
Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138
PHONE
+1 973-832-8147
SUBSIDIARIES
Vyome Therapeutics, Inc.
OFFICE
Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138
Vyome Therapeutics Limited, Subsidiary of Vyome Therapeutics, Inc.
OFFICE
Plot No. 465, Ground Floor, F.I.E., Patparganj Industrial Area, Delhi, India- 110092.
PHONE
+91-99682-17333
*Certain statements on this site are forward-looking within the meaning of federal securities laws. Please see our full disclaimer here.
A Cambridge, MA, based global healthcare platform synergizing biotech, medical devices, and AI.
Vyome Holdings, Inc.
Nasdaq: HIND
PRINCIPAL OFFICE
Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138
PHONE
+1 973-832-8147
SUBSIDIARIES
Vyome Therapeutics, Inc.
OFFICE
Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138
Vyome Therapeutics Limited, Subsidiary of Vyome Therapeutics, Inc.
OFFICE
Plot No. 465, Ground Floor, F.I.E., Patparganj Industrial Area, Delhi, India- 110092.
PHONE
+91-99682-17333
*Certain statements on this site are forward-looking within the meaning of federal securities laws. Please see our full disclaimer here.